165 related articles for article (PubMed ID: 17671332)
1. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro.
Liu J; Li J; Rosol TJ; Pan X; Voorhees JL
Phys Med Biol; 2007 Aug; 52(16):4739-47. PubMed ID: 17671332
[TBL] [Abstract][Full Text] [Related]
2. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
[TBL] [Abstract][Full Text] [Related]
3. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
[TBL] [Abstract][Full Text] [Related]
4. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
5. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Liu Y; Li K; Liu B; Feng SS
Biomaterials; 2010 Dec; 31(35):9145-55. PubMed ID: 20864169
[TBL] [Abstract][Full Text] [Related]
6. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
7. Targeted Fe-doped silica nanoparticles as a novel ultrasound-magnetic resonance dual-mode imaging contrast agent for HER2-positive breast cancer.
Li X; Xia S; Zhou W; Ji R; Zhan W
Int J Nanomedicine; 2019; 14():2397-2413. PubMed ID: 31040664
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F
Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322
[TBL] [Abstract][Full Text] [Related]
9. Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions.
Hainfeld JF; O'Connor MJ; Dilmanian FA; Slatkin DN; Adams DJ; Smilowitz HM
Br J Radiol; 2011 Jun; 84(1002):526-33. PubMed ID: 21081567
[TBL] [Abstract][Full Text] [Related]
10. The in vitro study of Her-2 targeted gold nanoshell liquid fluorocarbon poly lactic-co-glycolic acid ultrasound microcapsule for ultrasound imaging and breast tumor photothermal therapy.
Zhang Y; Wan CF; Du J; Dong Q; Wang YY; Yang H; Li FH
J Biomater Sci Polym Ed; 2018 Jan; 29(1):57-73. PubMed ID: 29105559
[TBL] [Abstract][Full Text] [Related]
11. Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells.
Li J; Xu W; Yuan X; Chen H; Song H; Wang B; Han J
Int J Nanomedicine; 2017; 12():6909-6921. PubMed ID: 29075110
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent.
Milgroom A; Intrator M; Madhavan K; Mazzaro L; Shandas R; Liu B; Park D
Colloids Surf B Biointerfaces; 2014 Apr; 116():652-7. PubMed ID: 24269054
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
Jang M; Yoon YI; Kwon YS; Yoon TJ; Lee HJ; Hwang SI; Yun BL; Kim SM
Korean J Radiol; 2014; 15(4):411-22. PubMed ID: 25053899
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.
Sun B; Feng SS
Nanomedicine (Lond); 2009 Jun; 4(4):431-45. PubMed ID: 19505246
[TBL] [Abstract][Full Text] [Related]
15. Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.
Cheng YA; Wu TH; Wang YM; Cheng TL; Chen IJ; Lu YC; Chuang KH; Wang CK; Chen CY; Lin RA; Chen HJ; Liao TY; Liu ES; Chen FM
J Nanobiotechnology; 2020 Aug; 18(1):118. PubMed ID: 32854720
[TBL] [Abstract][Full Text] [Related]
16. Magnetic nanobubbles with potential for targeted drug delivery and trimodal imaging in breast cancer: an in vitro study.
Song W; Luo Y; Zhao Y; Liu X; Zhao J; Luo J; Zhang Q; Ran H; Wang Z; Guo D
Nanomedicine (Lond); 2017 May; 12(9):991-1009. PubMed ID: 28327075
[TBL] [Abstract][Full Text] [Related]
17. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y Y
Li J; Tian Y; Shan D; Gong A; Zeng L; Ren W; Xiang L; Gerhard E; Zhao J; Yang J; Wu A
Biomaterials; 2017 Feb; 116():106-117. PubMed ID: 27914983
[TBL] [Abstract][Full Text] [Related]
19. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles.
Kouchakzadeh H; Shojaosadati SA; Tahmasebi F; Shokri F
Int J Pharm; 2013 Apr; 447(1-2):62-9. PubMed ID: 23454849
[TBL] [Abstract][Full Text] [Related]
20. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
